Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06511921
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-07-12
Brief Title:
Effect of Biologic Therapy on Surgical Outcomes for Perforated Crohns Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Early Versus Late Biologic Therapy for Post-operative Perforated Crohns Disease Patients Diagnosed for the First Time
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
crohns disease patients who present by intestinal perforation as the first presentation are hard to deal with Surgical techniques as anastmosis or diversion stoma and active course of the disease may greatly affect the quality of life In post-operative period is the priority to avoid the post operative complications and to improve surgical outcomes or to stop active course of the disease and to induce remission So those patients were classified into two groups one group will receive biological therapy early post operative and the other group will receive it 2 or 3 months later after surgery and the investigators will compare results between the two groups
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None